BioSpace News Archive

Gilead Sciences, Inc. today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance of expanded energy settings for use with the family of CellFX System treatments tips in dermatology.

Lucid Diagnostics Inc. announced that a recently published American Gastroenterological Association clinical practice update supports esophageal precancer screening to prevent highly lethal esophageal cancer utilizing its EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Cell Collection Device.

Salarius Pharmaceuticals, Inc. announces the addition of four prestigious institutions to the open-label Phase 1/2 trial with seclidemstat in Ewing’s sarcoma and FET-rearranged sarcomas.

Vaxcyte, Inc. (Nasdaq: PCVX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in adults ages 18 and older.

Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pK a ).

NeuroOne Medical Technologies Corporation will host a conference call to discuss financial results for its third quarter of fiscal 2022 ended June 30, 2022.

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announces today that it has launched a new website Necrobiosislipoidicastudy.com.

Children’s Hospital of Philadelphia has received a $400,000 grant from the American Heart Association to help study heart-secreted hormones.

Viome Life Sciences, a mission-driven biotechnology company, announces the arrival of its CancerDetect™ test for oral & throat cancer, the first to launch in a series of diagnostic tests in development.